CLAIMS

1. A compound of Formula (I):



(I)

wherein R^1 represents a phenyl or napthyl group (each of which is substituted by one or more substituents independently selected from –OH, -C_{1-6}alkyl, C_{1-6}haloalkyl, -OCH_2OCH_3, -C_{1-6}alkoxy, -halogen,), or a mono or bicyclic heteroaryl group comprising 1, 2 or 3 nitrogen atoms, optionally substituted by -C_{1-6}alkoxy, -C_{1-6}alkyl, C_{1-6}haloalkyl or =0;

R^2 represents H, benzoimidazolyl, benzothiazolyl, isoquinolinyl, or quinolinyl group or phenyl (said phenyl being optionally substituted by -NR^3R^4, -C_{1-4}alkoxy, -C_{1-6}alkyl, -$CONR^3R^4$, -$SO_2NR^3R^4$, -$NHCONR^3R^4$, -$NHCOC_{1-6}$alkyl, -C_{1-6}haloalkyl, -OCH_2O-, -phenoxy (wherein the phenyl moiety is optionally substituted by NH_2), -C_{1-3}alkyl, -C_{1-3}alkoxy, -CF_3, -5 membered heteroaryl group comprising one or two nitrogen atoms).

R^3 and R^4 are independently selected from H, -C_{1-6}alkyl, -C_{1-3}alkylNR^5R^6;

R^5 and R^6 are independently H or C_{1-3}alkyl;

or a salt, solvate, or physiologically functional derivative thereof.

2. A compound according to claim 1 wherein R^1 phenyl (substituted by one or more substituents selected from $-OCH_2OCH_3$, -OH, -halogen, $-OCH_3$), naphthyl (substituted by OH), indolinyl, quinolinyl or a pyridinyl moiety (wherein the pyridinyl moiety is optionally substituted by $-OCH_3$ or = O).

3. A compound according to claim 2 wherein R^1 is phenyl substituted by OH.

4. A compound according to claim 3 wherein the OH is on the 5 position of the phenyl ring.

5. A compound according to claims 1 – 4 wherein R^2 is H, quinoline, phenyl (optionally substituted by $-SO_2NH_2$, CF_3, $-CONH_2$, -imidazolyl, $-OCH_3$, C_{1-3} alkyl, $-OCH_20-$, CONH CH_2CH_2 $N(CH_2CH_3)$, -O-phenyl (where the phenyl is substituted by NH_2), $-NHCOCH_3$, NH_2, $NHCOCH_3$,) or benzoimidazolyl or benzothiazolyl moiety.

6. A compound according to claim 5 where in R^2 is a quinoline moiety, a quinoline 6-yl moiety.

7. A compound according to claim 6 wherein R^2 is a quinoline 6-yl moiety.

8. A compound as claimed in claim 1, selected from the group consisting of:

5-(Indol-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;
5-(2-Methoxypyridin-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;
5-(Pyridin-2-on-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;
5-(4-Methoxymethyoxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
5-(4-Hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
5-(3-Fluoro-4-hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
1-Amino-5-(indol-5-yl)isoquinoline;
1-Amino-5-(2-methoxypyridin-5-yl)isoquinoline;
1-Amino-5-(pyridin-2-on-5-yl)isoquinoline;

1-Amino-5-(3-methoxyphenyl)isoquinoline;

5-(2-Hydroxynaphthalen-6-yl)-1-(quinolin-6-yl)aminoisoquinoline;

5-(4-Chloro-3-hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;

3-[5-(4-Chloro-3-hydroxyphenyl)-isoquinolin-1-ylamino]benzenesulfonamide;

5-(3-Hydroxyphenyl)-1-(4-trifluoromethylphenyl)aminoisoquinoline;

5-(3-Hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;

1-(4-Aminocarbonylphenyl)amino-5-(3-hydroxyphenyl)isoquinoline;

5-(3-Hydroxyphenyl)-1-[4-(imidazol-1-yl)phenyl]aminoisoquinoline;

3-[5-(3-Hydroxyphenyl)-isoquinolin-1-ylamino]benzenesulfonamide;

5-(3-Hydroxyphenyl)-1-(3-methoxyphenyl)aminoisoquinoline;

1-(3-Ethylphenyl)amino-5-(3-hydroxyphenyl)isoquinoline;

N-(2-Diethylaminoethyl)-4-[5-(3-hydroxyphenyl)isoquinolin-1-ylamino]benzamide;

1-(3-(4-Aminophenoxy)phenyl)amino-5-(3-hydroxyphenyl)isoquinoline;

5-(3-Hydroxyphenyl)-1-phenylaminoisoquinoline;

5-(3-Hydroxyphenyl)-1-(3,4-methylenedioxyphenyl)aminoisoquinoline;

1-Amino-5-(3-hydroxyphenyl)isoquinoline;

1-(Benzothiazol-6-yl)amino-5-(3-hydroxyphenyl)isoquinoline

1-(Benzimidazol-5-yl)amino-5-(3-hydroxyphenyl)isoquinoline

1-(3-Aminophenyl)amino-5-(3-hydroxyphenyl)isoquinoline

{3-[5-(3-Hydroxyphenyl)isoquinolin-1-ylamino]phenyl}urea

N-{3-[5-(3-Hydroxyphenyl)isoquinolin-1-ylamino]phenyl}acetamide;

or a salt, solvate, or physiologically functional derivative thereof.

9. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in any one of claims 1 - 8, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

10. A compound as claimed in any of claims 1 - 8, or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.

11. A compound as claimed in any of claims 1 - 8, or a salt, solvate, or a physiologically functional derivative thereof for use in treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate ALK5 activity.

12. A compound as claimed in any of claims 1 - 8, or a salt, solvate, or a physiologically functional derivative thereof for use in treating chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.

13. A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate ALK5 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 - 8, or a salt, solvate, or a physiologically functional derivative thereof.

14. A method according to claim 13 wherein the disorder mediated by inappropriate ALK5 activity is chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B

virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.

15. Use of a compound as claimed in any of claims 1 - 8, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by inappropriate ALK5 activity.

16. Use according to claim 15 wherein the disorder mediated by inappropiate ALK5 activity is chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.